MONTREAL, Dec. 14 /CNW Telbec/ - Ranaz Corporation ("Ranaz" or the
"Corporation") (TSX-V: RNZ), a company specializing in the manufacturing and
marketing of protein and dietary supplements for weight loss and obesity
treatment, announced today that its ProtiLife brand of products is distributed
throughout the Katz Group pharmacy network, namely in Pharma Plus, Rexall,
I.D.A. and Guardian stores, which comprises over 1,000 corporate, franchise
and independent pharmacies across Canada.
This latest success, on the heels of other agreements signed recently by
Ranaz, strengthens the Canadian market position of the Corporation's new brand
of ProtiLife weight-loss products, which will now be available in over 4,000
Canadian sales outlets. "We are pleased that the Katz Group enables us to
offer our ProtiLife products in its large network of pharmacies across the
country," said Ranaz President and Chief Executive Officer Jean
Bourassa-Marineau. "This latest milestone is an additional testimony to our
expertise and reputation in the innovative formulation and development of
effective and delicious weight-loss products."
Ranaz has been manufacturing a full line of products for distribution
through specialized channels in Canada, Europe and the United States for the
past 17 years.
ProtiLife Brand Products
The ProtiLife brand enables Ranaz to capitalize on its experience in
developing weight-loss and obesity treatment products by introducing a
mass-market product supported by scientific research. The Corporation wishes
to position this brand to eventually establish itself as a world-class leader
in the development and marketing of quality and effective high-protein weight
loss and health supplements, and for its consumer market expertise.
About Ranaz Corporation
Ranaz is a corporation specializing in the manufacture and marketing of
protein and dietary supplements in relation to weight loss and obesity
treatments. Its mission is to design, develop and market nutritional, protein
and dietary supplements under its own corporate brands, such as Protidiet and
ProtiLife, as well as under private labels.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Ranaz's control.
Such risks include but are not limited to: the impact of general economic
conditions, changes in the regulatory environment in the jurisdictions in
which Ranaz does business, stock markets volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation, as well as
other risks disclosed in public filings of Ranaz. Consequently, actual future
results may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Ranaz is under no obligation and
disavows any intention to update or revise such statements as a result of any
event, circumstances or otherwise.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Ranaz Corporation: Martin Vidal, Executive Vice
President, (450) 491-7106 ext. 213, email@example.com; SOLAK
Communications: François Kalos, President, (450) 993-0828, firstname.lastname@example.org;
Media: Impact Communication, Carlo Tarini, President, (514) 916-2436,